Medicago Inc. (MDG.V) announced additional positive results for its H5N1 Avian Influenza VLP vaccine from a pre-clinical immunogenicity study performed in ferrets. The results of the study showed that H5N1 VLP vaccine induced antibodies that neutralized strains of H5N1 circulating virus beyond the strain used to develop the original vaccine. The study demonstrated cross-reactivity against three deadliest strains of H5N1, namely Turkey strain, Anhui strain, and Vietnam strain.
The company said the objective of pre-clinical immunogenicity study was to evaluate the optimal dosage of H5N1 VLP vaccine in ferrets, the most predictive animal model used for the purpose.
For comments and feedback: editorial@rttnews.com